Adding an SGLT2 Inhibitor Means Less Insulin for T2DM Patients

Adding an SGLT2 inhibitor to insulin therapy for patients with type 2 diabetes who’d required large doses of insulin helped them reduce their insulin dose.

Hypoglycemia and weight gain are a common side effect of insulin therapy, but what if we use it as dual therapy in combination with SGLT2 inhibitors? Do those side effects remain the same or there is an improvement in the quality of life of patients who have diabetes mellitus (T2DM)?

Delays in the optimization of glycemic control therapy can result in cardiovascular events, renal problems, blindness, and other conditions. he addition of SGLT2 inhibitors to the insulin therapy in patients with T2DM can reduce common side effects of insulin therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *